{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:04:05Z","timestamp":1793660645529,"version":"4.5.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007102","name":"Zagazig University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007102","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metastatic M\u00fcllerian carcinomas, including endometrial and ovarian adenocarcinomas, are challenging to diagnose due to factors like similar malignancies, insufficient clinical history, multiorgan dissemination, and small tumor specimens. Immunohistochemistry (IHC) stains are commonly used to identify these cancers. PAX8 is a widely used IHC marker with varying sensitivity levels for different types of gynecologic carcinomas. SOX17, a transcription factor involved in embryonic differentiation and development, has high specificity for ovarian and endometrial carcinomas but is weakly expressed in other epithelial neoplasms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>. 56 endometrial carcinomas cases,56 ovarian cancer case and 56 cases of non-gynecological cancer, were subjected to immunohistochemical (IHC) analysis of SOX17 and PAX8.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In endometrial carcinomas, PAX8-high\/SOX17-high co-expression strongly favored endometrioid histology (90% vs. 68.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04), while ovarian high-grade serous carcinomas commonly expressed PAX8 (78.9% high) with heterogeneous SOX17 expression (47.4% high). Notably, double-negative PAX8\/SOX17 status completely excluded M\u00fcllerian origin in metastases from colorectal, breast, and pulmonary primary tumors (100% specificity), though renal (all PAX8+) and thyroid neoplasms (63.6% PAX8+) required additional markers for distinction. Statistical analyses confirmed subtype-specific trends (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 for all applicable comparisons) with loss of SOX17 associated with aggressive histotypes (25% negative in serous versus 10% in endometrioid).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>M\u00fcllerian carcinomas can be distinguished from non-gynecological metastases using PAX8 and SOX17 immunohistochemistry, with PAX8-high\/SOX17-high patterns strongly indicating endometrioid differentiation and double-negative results excluding gynecologic origin with consistency in colorectal, breast, and pulmonary carcinomas. Renal and thyroid carcinomas are the diagnostic traps on the basis of PAX8 expression and require additional markers for final classification in metastatic workups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13000-026-01746-2","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T01:35:08Z","timestamp":1770687308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["SOX17\/PAX8 dual immunohistochemical expression in the diagnosis of M\u00fcllerian carcinomas"],"prefix":"10.1186","volume":"21","author":[{"given":"Manar","family":"Moustafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa Ahmed Mohamed","family":"Abdalrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba Mahmoud","family":"Abdelgeleel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"issue":"2","key":"1746_CR1","doi-asserted-by":"publisher","first-page":"100001","DOI":"10.1016\/j.modpat.2022.100001","volume":"36","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yao J, Niu N, Li X, Liu Y, Huo L, Euscher ED, Wang H, Bell D, Sood AK, Wang G, Lawson BC, Ramalingam P, Malpica A, Sahin AA, Ding Q, Liu J. SOX17: A highly sensitive and specific immunomarker for ovarian and endometrial carcinomas. Mod Pathol. 2023;36(2):100001. https:\/\/doi.org\/10.1016\/j.modpat.2022.100001.","journal-title":"Mod Pathol"},{"key":"1746_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.humpath.2022.04.007","volume":"125","author":"T Shen","year":"2022","unstructured":"Shen T, Zhao J, Zhao M, Taggart MW, Ramalingam P, Gong Y, Wu Y, Liu H, Zhang J, Resetkova E, Wang WL, Ding Q, Huo L, Yoon E. Unusual staining of immunohistochemical markers PAX8 and CDX2 in breast carcinoma: a potential diagnostic pitfall. Hum Pathol. 2022;125:35\u201347. https:\/\/doi.org\/10.1016\/j.humpath.2022.04.007. Epub 2022 Apr 10.","journal-title":"Hum Pathol"},{"issue":"4","key":"1746_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/PAI.0000000000000883","volume":"29","author":"S Lu","year":"2021","unstructured":"Lu S, Yakirevich E, Hart J, Wang L, Wang Y. PAX8 expression in breast cancer. Appl Immunohistochem Mol Morphol. 2021;29(4):293\u20138. https:\/\/doi.org\/10.1097\/PAI.0000000000000883.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"7","key":"1746_CR4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/PAI.0000000000000796","volume":"28","author":"K Singh","year":"2020","unstructured":"Singh K, Hanley LC, Sung CJ, Quddus MR. Comparison of PAX8 expression in breast carcinoma using MRQ50 and BC12 monoclonal antibodies. Appl Immunohistochem Mol Morphol. 2020;28(7):558\u201361. https:\/\/doi.org\/10.1097\/PAI.0000000000000796.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"10","key":"1746_CR5","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.21873\/anticanres.14613","volume":"40","author":"SW Kim","year":"2020","unstructured":"Kim SW, Kim HS, Na K. Characterization of paired box 8 (PAX8)-expressing metastatic breast carcinoma. Anticancer Res. 2020;40(10):5925\u201332. https:\/\/doi.org\/10.21873\/anticanres.14613.","journal-title":"Anticancer Res"},{"issue":"9","key":"1746_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/PAI.0000000000000707","volume":"27","author":"MR Kilgore","year":"2019","unstructured":"Kilgore MR, Bosch DE, Adamson KH, Swanson PE, Dintzis SM, Rendi MH. Unexpected PAX8 immunoreactivity in metastatic High-grade breast cancer. Appl Immunohistochem Mol Morphol. 2019;27(9):637\u201343. https:\/\/doi.org\/10.1097\/PAI.0000000000000707.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"7","key":"1746_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/cncy.22708","volume":"131","author":"S Satturwar","year":"2023","unstructured":"Satturwar S, Shaker N, Sinclair W, Shen R, Parwani AV, Ding Q, Li Z. SOX17 is a highly sensitive and specific marker for metastatic ovarian and endometrial carcinomas in cytology cell block specimens. Cancer Cytopathol. 2023;131(7):465\u201370. https:\/\/doi.org\/10.1002\/cncy.22708. Epub 2023 May 17.","journal-title":"Cancer Cytopathol"},{"issue":"pt 1","key":"1746_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.semcancer.2019.08.008","volume":"67","author":"DS Tan","year":"2020","unstructured":"Tan DS, Holzner M, Weng M, Srivastava Y, Jauch R. SOX17 in cellular reprogramming and cancer. Semin Cancer Biol. 2020;67(pt 1):65\u201373. https:\/\/doi.org\/10.1016\/j.semcancer.2019.08.008.","journal-title":"Semin Cancer Biol"},{"issue":"1\u20132","key":"1746_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cell.2014.12.013","volume":"160","author":"N Irie","year":"2015","unstructured":"Irie N, Weinberger L, Tang WW, et al. SOX17 is a critical specifier of human primordial germ cell fate. Cell. 2015;160(1\u20132):253\u201368. https:\/\/doi.org\/10.1016\/j.cell.2014.12.013.","journal-title":"Cell"},{"issue":"11","key":"1746_CR10","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1161\/circresaha.120.318220","volume":"127","author":"M Han","year":"2020","unstructured":"Han M, Zhou B. Sox17 and coronary arteriogenesis in development. Circ Res. 2020;127(11):1381\u20133. https:\/\/doi.org\/10.1161\/circresaha.120.318220.","journal-title":"Circ Res"},{"issue":"12","key":"1746_CR11","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/s41388-022-02210-3","volume":"41","author":"L Lin","year":"2022","unstructured":"Lin L, Shi K, Zhou S, et al. SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer. Oncogene. 2022;41(12):1767\u201379. https:\/\/doi.org\/10.1038\/s41388-022-02210-3.","journal-title":"Oncogene"},{"issue":"728","key":"1746_CR12","doi-asserted-by":"publisher","first-page":"eabm2496","DOI":"10.1126\/scisignal.abm2496","volume":"15","author":"D Chaves-Moreira","year":"2022","unstructured":"Chaves-Moreira D, Mitchell MA, Arruza C, et al. The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17. Sci Signal. 2022;15(728):eabm2496. https:\/\/doi.org\/10.1126\/scisignal.abm2496.","journal-title":"Sci Signal"},{"issue":"3","key":"1746_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/his.13980","volume":"76","author":"ANH Hopman","year":"2020","unstructured":"Hopman ANH, Moshi JM, Hoogduin KJ, et al. SOX17 expression and its down-regulation by promoter methylation in cervical adenocarcinoma in situ and adenocarcinoma. Histopathology. 2020;76(3):383\u201393. https:\/\/doi.org\/10.1111\/his.13980.","journal-title":"Histopathology"},{"issue":"46","key":"1746_CR14","doi-asserted-by":"publisher","first-page":"76036","DOI":"10.18632\/oncotarget.12582","volume":"7","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Bao W, Wang K, et al. SOX17 is a tumor suppressor in endometrial cancer. Oncotarget. 2016;7(46):76036\u201346. https:\/\/doi.org\/10.18632\/oncotarget.12582.","journal-title":"Oncotarget"},{"issue":"15","key":"1746_CR15","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1101\/gad.2052911","volume":"25","author":"S He","year":"2011","unstructured":"He S, Kim I, Lim MS, Morrison SJ. Sox17 expression confers self-renewal potential and fetal stem cell characteristics upon adult hematopoietic progenitors. Genes Dev. 2011;25(15):1613\u201327. https:\/\/doi.org\/10.1101\/gad.2052911.","journal-title":"Genes Dev"},{"issue":"3","key":"1746_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.stem.2011.01.017","volume":"8","author":"P Wang","year":"2011","unstructured":"Wang P, Rodriguez RT, Wang J, Ghodasara A, Kim SK. Targeting SOX17 in human embryonic stem cells creates unique strategies for isolating and analyzing developing endoderm. Cell Stem Cell. 2011;8(3):335\u201346. https:\/\/doi.org\/10.1016\/j.stem.2011.01.017.","journal-title":"Cell Stem Cell"},{"issue":"Pt 1","key":"1746_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.semcancer.2019.03.004","volume":"67","author":"D Grimm","year":"2020","unstructured":"Grimm D, Bauer J, Wise P, Kr\u00fcger M, Simonsen U, Wehland M, Infanger M, Corydon TJ. The role of SOX family members in solid tumours and metastasis. Semin Cancer Biol. 2020;67(Pt 1):122\u201353. Epub 2019 Mar 23.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1746_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/ajcp\/aqae104","volume":"163","author":"BZ Clark","year":"2025","unstructured":"Clark BZ, Soong TR, Goel K, Elishaev E, Zhao C, Jones TE, Jones MW, Skvarca LB, Motanagh SA, Carter GJ, Fine JL, Harinath L, Villatoro TM, Yu J, Bhargava R. A comprehensive analysis of SOX17 expression by immunohistochemistry in human epithelial tumors, with an emphasis on gynecologic tumors. Am J Clin Pathol. 2025;163(1):143\u201352. https:\/\/doi.org\/10.1093\/ajcp\/aqae104.","journal-title":"Am J Clin Pathol"},{"issue":"40","key":"1746_CR19","doi-asserted-by":"publisher","first-page":"68758","DOI":"10.18632\/oncotarget.20213","volume":"8","author":"CJ Walker","year":"2017","unstructured":"Walker CJ, O\u2019Hern MJ, Serna VA, et al. Novel SOX17 frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations. Oncotarget. 2017;8(40):68758\u201368. https:\/\/doi.org\/10.18632\/oncotarget.20213. Published 2017 Aug 12.","journal-title":"Oncotarget"},{"issue":"5","key":"1746_CR20","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/PGP.0b013e3182a54afa","volume":"33","author":"A Yemelyanova","year":"2014","unstructured":"Yemelyanova A, Gown AM, Wu LS, Holmes BJ, Ronnett BM, Vang R. PAX8 expression in uterine adenocarcinomas and mesonephric proliferations. Int J Gynecol Pathol. 2014;33(5):492\u20139. https:\/\/doi.org\/10.1097\/PGP.0b013e3182a54afa.","journal-title":"Int J Gynecol Pathol"},{"issue":"6","key":"1746_CR21","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/PAS.0b013e318216c112","volume":"35","author":"AR Laury","year":"2011","unstructured":"Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, Drapkin R, Hirsch MS. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011;35(6):816\u201326. https:\/\/doi.org\/10.1097\/PAS.0b013e318216c112.","journal-title":"Am J Surg Pathol"},{"issue":"13","key":"1746_CR22","doi-asserted-by":"publisher","first-page":"7410","DOI":"10.3390\/ijms23137410","volume":"23","author":"RR Kakun","year":"2022","unstructured":"Kakun RR, Melamed Z, Perets R. PAX8 in the junction between development and tumorigenesis. Int J Mol Sci. 2022;23(13):7410. https:\/\/doi.org\/10.3390\/ijms23137410. Published 2022 Jul 3.","journal-title":"Int J Mol Sci"},{"key":"1746_CR23","doi-asserted-by":"publisher","unstructured":"Tahir M, Xing D, Ding Q, Wang Y, Singh K, Suarez AA, Parwani A, Li Z. Identifying mesonephric-like adenocarcinoma of the endometrium by combining SOX17 and PAX8 immunohistochemistry. Histopathology. 2025;86(2):268\u2013277. https:\/\/doi.org\/10.1111\/his.15312. Epub 2024 Sep 4. PMID: 39233315.","DOI":"10.1111\/his.15312"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-026-01746-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-026-01746-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-026-01746-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T15:03:57Z","timestamp":1771945437000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13000-026-01746-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1746"],"URL":"https:\/\/doi.org\/10.1186\/s13000-026-01746-2","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was carried out after approval by the local ethical council, Zagazig University, Institutional Review Board (IRB) for human studies (reference number is ZU-IRB :1634\/7-Oct-2025).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}